Montag A & Associates Inc. Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Montag A & Associates Inc. cut its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,860 shares of the company's stock after selling 3,130 shares during the quarter. Montag A & Associates Inc.'s holdings in Johnson & Johnson were worth $15,732,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC increased its holdings in shares of Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares during the last quarter. Washington Trust Bank increased its holdings in shares of Johnson & Johnson by 4.5% during the 4th quarter. Washington Trust Bank now owns 19,163 shares of the company's stock worth $2,771,000 after buying an additional 828 shares during the last quarter. Millstone Evans Group LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $1,449,000. Finally, ZEGA Investments LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $945,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE JNJ opened at $163.65 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm's 50 day moving average price is $154.29 and its 200 day moving average price is $155.05. The firm has a market cap of $393.75 billion, a P/E ratio of 17.50, a price-to-earnings-growth ratio of 2.19 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business earned $2.82 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.18%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Analyst Ratings Changes

JNJ has been the topic of a number of recent research reports. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. UBS Group reiterated a "buy" rating and set a $190.00 target price (up previously from $180.00) on shares of Johnson & Johnson in a research note on Thursday. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $172.87.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.